{
  "docId": "019de517-75a1-7387-968b-d0dc513bf421",
  "docSlug": "e930bfcc8684afb6f5a4dd5442b5166d",
  "documentTitle": "Ocuphire Pharma | Investor Presentation Deck | 42 slides",
  "authorId": "ocuphire-pharma",
  "authorName": "Ocuphire Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 42,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de517-75a1-7387-968b-d0dc513bf421/3",
  "deckHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421",
  "deckJsonHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421.json",
  "deckAnchorHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.08,
        "x": 0.04,
        "y": 0.93
      },
      "kind": "image",
      "text": "Ocuphire Pharma",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a9a861d-f57a-46ce-a530-53cefc8c5d7c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.69,
        "w": 0.95,
        "x": 0.039,
        "y": 0.18
      },
      "kind": "table",
      "text": "Product Candidate: APX3330 (Oral Pill), APX3330 (Local Delivery), APX2009 and APX2014 (Local Delivery), Phentolamine Ophthalmic Solution 0.75% (Eyedrops)\nIndication: Diabetic Retinopathy (DR), Retina, Retina, Pharmacologically-Induced Mydriasis, Presbyopia (P), Dim Light or Night Vision Disturbances (DLD)\nPre-clinical, Phase 1, Phase 2, Phase 3, Regulatory Approval\nUpcoming Milestones: EOP2 Mtg October 2023, Special Protocol Assessment (SPA) Submission, Select retinal drug delivery technology, APPROVED (RYZUMVIT™) Sept 2023, VEGA-2 Phase 3 Topline Data Q4 2023, SPA Submitted, LYNX-2 2nd Phase 3 trial (n=150+)",
      "attrs": {},
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa9763d6-0673-44cf-9a67-ca8ad453e26d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.33,
        "x": 0.046,
        "y": 0.056
      },
      "kind": "title",
      "text": "Ocuphire Pipeline",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "57235949-d5e2-46bb-b828-e4419519285c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 1,
      "beatId": "84e4008d-7221-45f0-9cd1-2bf80e7c9928",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Situation & Context",
      "beatSlug": "consultants-gambit-situation-context",
      "evidence": "Slides 1-5 provide an overview of Ocuphire Pharma and its pipeline",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Setup",
      "parentBeatSlug": "setup"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}